Quantum-Si (QSI) Registration Filing summary

Company overview and business model

• Focuses on proteomics research, offering a proprietary single-molecule detection platform for Next-Gen Protein Sequencing (NGPS) to enable massively parallel protein sequencing and analysis.

• Platform includes Platinum NGPS instrument, analysis software, and consumable kits, with commercial launches in 2023–2024 and a new benchtop sequencer in 2025.

• Aims to address bottlenecks in legacy proteomics tools by reducing instrument cost and complexity, targeting broad research and clinical applications.

Financial performance and metrics

• As of June 30, 2025, 164,357,534 shares of Class A common stock were outstanding.

• Recent direct offering in July 2025 raised $50 million gross, with $46.9 million net proceeds after fees.

• Historical net tangible book value as of June 30, 2025 was $1.20 per share; pro forma as adjusted after recent offerings is $1.30 per share.

Use of proceeds and capital allocation

• Net proceeds will support product development (including the Proteus platform), commercialization, manufacturing, R&D, working capital, capital expenditures, and general corporate purposes.

• Pending use, proceeds may be invested in short-term, investment-grade securities or U.S. government obligations.